Measuring quality in arthritis care: The arthritis foundation's quality indicator set for analgesics

Arthritis Care and Research

Volumn 51, Issue 3, 2004, Pages 337-349

  Saag, Kenneth G ^a   Olivieri, Jason J ^a   Patino, Fausto ^a   Mikuls, Ted R ^b   Allison, Jeroan J ^a   MacLean, Catherine H ^c,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c RAND CORPORATION   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesics; NSAIDs; Patient safety; Quality indicators

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; WARFARIN;

ANALGESIA; ARTHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG MONITORING; DRUG SAFETY; DUODENUM ULCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROTOXICITY; OSTEOARTHRITIS; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STOMACH ULCER; SYSTEMATIC REVIEW;

EID: 2642546648     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20422     Document Type: Review

References (89)

1. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1985;28:686-92.
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-44.
3. Holt WS Jr, Mazzuca SA. Prescribing behaviors of family physicians in the treatment of osteoarthritis. Fam Med 1992; 24:524-7.
4. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998;25:408-16.
5. Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 2000;27:1648-55.
6. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000;151:488-96.
7. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 1996;156:2433-9.
8. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal antiinflammatory drugs. N Engl J Med 1994;331: 1675-9.
9. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991;115:165-72.
10. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991;115:787-96.
11. Hernandez-Diaz S, Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000;160: 2093-9.
12. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
13. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996;156: 1530-6.
14. Henrich WL, Agodoa LE, Barrett B, Bennett WM, Blantz RC, Buckalew VM Jr, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27: 162-5.
15. Tannenbaum H, Davis P, Russell AS, Atkinson MH, Maksymowych W, Huang SH, et al. Canadian NSAID Consensus Participants. An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. CMAJ 1996;155:77-88.
16. Tannenbaum H, Peloso PM, Russell AS, Marlow B. An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: the second Canadian consensus conference. Can J Clin Pharmacol 2000;7 Suppl A:4A-16A.
17. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328-46.
18. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713-22.
19. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40.
20. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6.
21. Eccles M, Freemantle N, Mason J, The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998;317:526-30.
22. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-60.
23. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, et al. Controversies in COX-2 selective inhibition. J Rheumatol 2002;29:1501-10.
24. Lanza FL, Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998;93:2037-46.
25. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring Quality in Arthritis Care: Methods for Developing the Arthritis Foundation's Quality Indicator Set. Arthritis Rheum 2004;51:193-202.
26. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med 2001;135:647-52.
27. Bollini P, Garcia Rodriguez LA, Perez Gutthann S, Walker AM. The impact of research quality and study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on upper gastrointestinal tract disease. Arch Intern Med 1992;152:1289-95.
28. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12.
29. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
30. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Celecoxib Long-term Arthritis Safety Study. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
31. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
32. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
33. Lu H. Statistical Reviewer Briefing Document for the Advisory Committee. Accessed January 15, 2002. URL: www. fda.gov/ohrms/dockets/ac/01/briefing/3677b1_04_stats.doc.
34. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999;26 Suppl 56:18-24.
35. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995;141:539-45.
36. Hallas J, Lauritsen J, Villadsen HD, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438-44.
37. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
38. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
39. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
40. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000;160:2998-3003.
41. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, et al. Rofecoxib/Ibuprofen Comparator Study Group. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
42. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30: 11-8.
43. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
44. Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA 2001;286:315-21.
45. Jick H, Derby LE, Garcia Rodriguez LA, Jick SS, Dean AD. Nonsteroidal antiinflammatory drugs and certain rare, serious adverse events: a cohort study. Pharmacotherapy 1993;13: 212-7.
46. Fox DA, Jick H. Nonsteroidal anti-inflammatory drugs and renal disease. JAMA 1984;251:1299-300.
47. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000;133:1-9.
48. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66:76-84.
49. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-41.
50. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
51. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000;43:1905-15.
52. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22: 767-73.
53. Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981;141(3 Spec No):380-5.
54. Johnston SC, Pelletier LL Jr. Enhanced hepatotoxicity of acetaminophen in the alcoholic patient: two case reports and a review of the literature. Medicine (Baltimore). 1997;76:185-91.
55. Schmidt LE, Dalhoff K, Poulsen HE. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. Hepatology 2002;35:876-82.
56. Schiodt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;337:1112-7.
57. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 1986;104:399-404.
58. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;272: 1845-50.
59. Eriksson LS, Broome U, Kalin M, Lindholm M. Hepatotoxicity due to repeated intake of low doses of paracetamol. J Intern Med 1992;231:567-70.
60. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology 1994; 19:1141-8.
61. Koch M, Dezi A, Ferrario F, Capurso I. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: a meta-analysis of randomized controlled clinical trials. Arch Intern Med 1996;156:2321-32.
62. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
63. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
64. Lanza FL, Kochman RL, Geis GS, Rack EM, Deysach LG. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits. Am J Gastroenterol 1991;86:1743-8.
65. Roth S, Agrawal N, Mahowald M, Montoya H, Robbins D, Miller S, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989;149:775-9.
66. Jiranek GC, Kimmey MB, Saunders DR, Willson RA, Shanahan W, Silverstein FE. Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study. Gastroenterology 1989;96(2 Pt 2 Suppl):656-61.
67. Ryan JR, Vargas R, Clay GA, McMahon FG. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 1987;83:41-6.
68. Silverstein FE, Kimmey MB, Saunders DR, Levine DS. Gastric protection by misoprostol against 1300 mg of aspirin: an endoscopic study. Dig Dis Sci 1986;31(2 Suppl):137S-41S.
69. Silverstein FE, Kimmey MB, Saunders DR, Surawicz CM, Willson RA, Silverman BA. Gastric protection by misoprostol against 1,300 mg of aspirin: an endoscopic dose-response study. Am J Med 1987;83:32-6.
70. Donnelly MT, Goddard AF, Filipowicz B, Morant SV, Shield MJ, Hawkey CJ. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000;14:529-34.
71. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 1994;39:97-103.
72. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-72.
73. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-70.
74. Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997;17:216-27.
75. Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged: a review of the literature. Med Decis Making 1999;19:428-34.
76. Edwards A, Elwyn G, Covey J, Matthews E, Pill R. Presenting risk information: a review of the effects of "framing" and other manipulations on patient outcomes. J Health Commun 2001; 6:61-82.
77. Rothenberg R, Holcombe J. Guidelines for Monitoring of NSAIDs: who listened? J Clin Rheumatol 2000;6:258-65.
78. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321: 1183-7.
79. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events: a critical analysis. J Clin Gastroenterol 1995; 21:13-6.
80. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 1993;35:219-26.
81. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
82. de Abajo FJ, Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1.
83. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343:834-9.
84. Evans JM, McGregor E, McMahon AD, McGilchrist MM, Jones MC, White G, et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. QJM 1995;88: 551-7.
85. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. Endstage renal disease and non-narcotic analgesics: a case-control study. Br J Clin Pharmacol 1990;30:717-23.
86. Pommer W, Bronder E, Greiser E, Helmert U, Jesdinsky HJ, Klimpel A, et al. Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol 1989;9:403-12.
87. Murray TG, Stolley PD, Anthony JC, Schinnar R, Hepler-Smith E, Jeffreys JL. Epidemiologic study of regular analgesic use and end-stage renal disease. Arch Intern Med 1983;143: 1687-93.
88. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-40.
89. Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol 2001;153: 1089-93.